Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Table 2 Baseline characteristics of PS-matched patients with and without inhibitors in the CHESS study^a

Characteristic	Patients who never developed inhibitors	Patients with current inhibitors	p-value^b
Characteristic	N = 58	N = 58	p-value^b
Demographics
Age, years
Mean ± SD	43.71 ± 17.17	41.90 ± 14.95	.4800
Median (range)	43 (18.00–88.00)	39.5 (18.00–80.00)
Race, N (%)
White	43 (74.1)	49 (84.5)	.1573
Body mass index
Mean ± SD	24.92 ± 2.67	25.31 ± 2.78	.4072
Median (range)	25.08 (15.57–32.02)	25.00 (20.52–32.83)
Hemophilia type, N (%)
Hemophilia A	47 (81.0)	47 (81.0)	1.0000
Comorbidities, N (%)
Alcohol dependence	7 (12.1)	4 (6.9)	.3173
Anemia	6 (10.3)	8 (13.8)	.5271
Anxiety	13 (22.4)	12 (20.7)	.8415
Depression	13 (22.4)	11 (19.0)	.6374
Diabetes mellitus	7 (12.1)	8 (13.8)	.7389
Fibromyalgia	3 (5.2)	7 (12.1)	.1573
Hepatitis B virus	1 (1.7)	1 (1.7)	1.0000
Hepatitis C virus	9 (15.5)	5 (8.6)	.2850
Human immunodeficiency virus	8 (13.8)	3 (5.2)	.0956
Hypertension	15 (25.9)	13 (22.4)	.6374
Hypercholesterolemia	7 (12.1)	5 (8.6)	.5271
Ischemic heart disease	4 (6.9)	3 (5.2)	.7055
Obesity	1 (1.7)	3 (5.2)	.3173
Osteoarthritis	7 (12.1)	8 (13.8)	.7815

Abbreviations: BMI body mass index, CHESS Cost of Haemophilia across Europe – a Socioeconomic Survey, PS propensity score, SD standard deviation
^aPatients with current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity status using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum sample size using the smallest caliper width
^bP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables and the McNemar’s test or exact McNemar’s test for categorical variables; p < .05 indicates statistical significance

ISSN: 1750-1172